Pfizer
Alison O'Neill has a strong legal background with extensive experience in M&A and licensing. Alison began their career as an Associate at Skadden, Arps, Slate, Meagher & Flom LLP & Affiliates in 2000, specializing in M&A. In 2006, they joined Wyeth as a Senior Corporate Counsel, where they worked until 2009. At Pfizer Inc., they served as an Assistant General Counsel for M&A and Licensing from 2009 until 2019. Currently, Alison holds the position of VP & Chief Counsel, M&A and Licensing at Pfizer.
Alison O'Neill earned a Bachelor of Science in Foreign Service, cum laude, from Georgetown University in the field of International Politics from 1993 to 1997. Alison then pursued a Doctor of Law (J.D.) degree from New York University School of Law from 1997 to 2000.
Pfizer
606 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.